DOP2013000169A - Compuesto para uso en el tratamiento de la artritis - Google Patents
Compuesto para uso en el tratamiento de la artritisInfo
- Publication number
- DOP2013000169A DOP2013000169A DO2013000169A DO2013000169A DOP2013000169A DO P2013000169 A DOP2013000169 A DO P2013000169A DO 2013000169 A DO2013000169 A DO 2013000169A DO 2013000169 A DO2013000169 A DO 2013000169A DO P2013000169 A DOP2013000169 A DO P2013000169A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- methyl
- arthritis
- composite
- treatment
- phenylsulfanyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
La presente invención se relaciona con compuesto N(4(4((4'-cloro(1,1'-bifenil)2-il)metil)piperazin-1-il)benzoil)-4-(((1R)-3-(dimetilamino)-1-((fenilsulfanil)metil)propil)amino)-3-nitrobencensulfonamida y compuesto N(4(4((2(4-clorofenil)5, 5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4- (((1R)-3-(morfolin-4-il)-1 -((fenilsulfanil)metil)propil)amino)-3-((trifluorometil) sulfonil) bencensulfonamida para uso en el tratamiento de la artritis en un mamífero.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98847907P | 2007-11-16 | 2007-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2013000169A true DOP2013000169A (es) | 2013-12-15 |
Family
ID=40291332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2013000169A DOP2013000169A (es) | 2007-11-16 | 2013-07-23 | Compuesto para uso en el tratamiento de la artritis |
Country Status (14)
Country | Link |
---|---|
US (2) | US20090176785A1 (es) |
EP (1) | EP2231159A1 (es) |
JP (2) | JP5450434B2 (es) |
KR (1) | KR101585848B1 (es) |
CN (1) | CN101969951B (es) |
AU (1) | AU2008322595B2 (es) |
CA (1) | CA2705294C (es) |
DO (1) | DOP2013000169A (es) |
IL (2) | IL205501A (es) |
MX (1) | MX2010005395A (es) |
NZ (2) | NZ601350A (es) |
RU (2) | RU2526201C2 (es) |
WO (1) | WO2009064938A1 (es) |
ZA (1) | ZA201003434B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
RU2568611C2 (ru) * | 2010-03-25 | 2015-11-20 | Эббви Инк. | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
US8722657B2 (en) | 2010-11-23 | 2014-05-13 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
WO2012071374A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Methods of treatment using selective bcl-2 inhibitors |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CA3073446A1 (en) | 2017-08-23 | 2019-02-28 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
KR20220098755A (ko) | 2019-11-05 | 2022-07-12 | 애브비 인코포레이티드 | 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘 |
WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
US20230295183A1 (en) | 2020-02-24 | 2023-09-21 | Newave Pharmaceutical Inc. | Hot melt extruded solid dispersions containing a bcl2 inhibitor |
WO2022140224A1 (en) | 2020-12-22 | 2022-06-30 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
JP3020612B2 (ja) * | 1995-10-10 | 2000-03-15 | ファイザー インク. | ロイコトリエンアンタゴニストとしてのインドールカルバメート類 |
KR20020081465A (ko) * | 2000-03-21 | 2002-10-26 | 더 프록터 앤드 갬블 캄파니 | 헤테로시클릭 측쇄 함유, n-치환된 메탈로프로테아제저해제 |
EP1415987B1 (en) * | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
BRPI0413072A (pt) * | 2003-07-28 | 2006-10-03 | Janssen Pharmaceutica Nv | moduladores de lta4h |
ES2441206T3 (es) * | 2003-09-03 | 2014-02-03 | Raqualia Pharma Inc. | Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2 |
WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
ES2257929B1 (es) * | 2004-07-16 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos. |
PT1888550E (pt) * | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
US20060276464A1 (en) * | 2005-05-13 | 2006-12-07 | Wyeth | Diarylsulfone sulfonamides and use thereof |
WO2008064116A2 (en) * | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
-
2008
- 2008-11-14 NZ NZ601350A patent/NZ601350A/xx not_active IP Right Cessation
- 2008-11-14 CN CN2008801242231A patent/CN101969951B/zh not_active Expired - Fee Related
- 2008-11-14 AU AU2008322595A patent/AU2008322595B2/en not_active Ceased
- 2008-11-14 JP JP2010534194A patent/JP5450434B2/ja not_active Expired - Fee Related
- 2008-11-14 NZ NZ585085A patent/NZ585085A/xx not_active IP Right Cessation
- 2008-11-14 RU RU2012143212/15A patent/RU2526201C2/ru not_active IP Right Cessation
- 2008-11-14 MX MX2010005395A patent/MX2010005395A/es active IP Right Grant
- 2008-11-14 US US12/270,987 patent/US20090176785A1/en not_active Abandoned
- 2008-11-14 KR KR1020107013163A patent/KR101585848B1/ko not_active IP Right Cessation
- 2008-11-14 WO PCT/US2008/083478 patent/WO2009064938A1/en active Application Filing
- 2008-11-14 EP EP08850262A patent/EP2231159A1/en not_active Withdrawn
- 2008-11-14 RU RU2010123796/15A patent/RU2472509C2/ru not_active IP Right Cessation
- 2008-11-14 CA CA2705294A patent/CA2705294C/en not_active Expired - Fee Related
-
2010
- 2010-05-02 IL IL205501A patent/IL205501A/en not_active IP Right Cessation
- 2010-05-14 ZA ZA2010/03434A patent/ZA201003434B/en unknown
-
2013
- 2013-07-23 DO DO2013000169A patent/DOP2013000169A/es unknown
- 2013-07-24 IL IL227641A patent/IL227641A0/en unknown
- 2013-11-11 JP JP2013232754A patent/JP5667684B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-17 US US14/972,429 patent/US20160101109A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR101585848B1 (ko) | 2016-01-15 |
RU2012143212A (ru) | 2014-04-20 |
CA2705294A1 (en) | 2009-05-22 |
KR20100099172A (ko) | 2010-09-10 |
RU2472509C2 (ru) | 2013-01-20 |
CA2705294C (en) | 2016-05-17 |
ZA201003434B (en) | 2011-10-26 |
JP5667684B2 (ja) | 2015-02-12 |
AU2008322595B2 (en) | 2014-01-30 |
AU2008322595A1 (en) | 2009-05-22 |
IL205501A0 (en) | 2010-12-30 |
NZ585085A (en) | 2012-08-31 |
MX2010005395A (es) | 2010-06-02 |
WO2009064938A1 (en) | 2009-05-22 |
IL205501A (en) | 2013-08-29 |
CN101969951A (zh) | 2011-02-09 |
JP2011503199A (ja) | 2011-01-27 |
US20160101109A1 (en) | 2016-04-14 |
EP2231159A1 (en) | 2010-09-29 |
JP5450434B2 (ja) | 2014-03-26 |
NZ601350A (en) | 2013-08-30 |
RU2526201C2 (ru) | 2014-08-20 |
IL227641A0 (en) | 2013-09-30 |
CN101969951B (zh) | 2012-10-31 |
WO2009064938A9 (en) | 2009-08-06 |
RU2010123796A (ru) | 2011-12-27 |
JP2014065716A (ja) | 2014-04-17 |
US20090176785A1 (en) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2013000169A (es) | Compuesto para uso en el tratamiento de la artritis | |
AR109816A2 (es) | Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2 | |
EA201200550A1 (ru) | Фармацевтические композиции, включающие bi-1356 и метформин | |
NZ598461A (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
BR122018014454B8 (pt) | forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol | |
CL2008000795A1 (es) | Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto. | |
ECSP077249A (es) | Nuevos hidratos y polimorfos de 4-[[(7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil]amino]-3-metoxi-n-(1-metil-4-piperidinil)-benzamida, procedimiento para su preparación y su uso como fármaco | |
AR057467A1 (es) | Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas | |
BRPI0820474B8 (pt) | uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo | |
CL2012001133A1 (es) | Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. | |
CL2008003271A1 (es) | Compuesto (2r)-2-[[(4-clorofenil)sulfonil][[2-fluoro-4-(1,2,4-oxadiazol-3-il)fenil]metil]amino]-5,5,5-trifluoropentanamida; composiciones farmaceuticas que lo contienen; y su uso en el tratamiento o retardo de la aparicion de la enfermedad de alzheimer, angiopatia amiloide cerebral, deterioro cognitivo leve y/o sindrome de down. | |
CY1109860T1 (el) | Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις | |
AR061481A1 (es) | Compuestos con actividad combinada sobre sert, 5-ht3 y 5-ht1a | |
CY1118976T1 (el) | Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης | |
CL2008002708A1 (es) | Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo, | |
ECSP19019613A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
HK1144940A1 (en) | Amine salts of a crth2 antagonist | |
CY1112433T1 (el) | Συνθεση ζιμποτεντανης που περιεχει μαννιτολη και μικροκρυσταλλικη κυτταρινη | |
CL2011003138A1 (es) | N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion. | |
CL2011002233A1 (es) | Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico. | |
RS54293B1 (en) | PHARMACEUTICAL COMBINATION | |
PE20150759A1 (es) | Antagonistas ccr3 arilsulfonamida | |
CL2007003009A1 (es) | N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del dolor, ansiedad y depresion. | |
CR20110082A (es) | Nuevos inhibidores de la proteina tirosina quinasa y receptores vegf-2 y uso farmacéutico de los mismos | |
EA200601410A1 (ru) | Новая комбинация агомелатина и ингибитора обратного поглощения норадреналина и фармацевтические композиции, которые её содержат |